# Meningococcal serogroups B vaccine (MenB) CDC recommendations- tabular CDSS rules (optimal)

Updated on 2024-05-02

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Vaccine** | **#** | **Age1** | **Age2** | **SpecialCondition** | **Immunization record** | | | **MedIndication1** | **MedIndication2** | **MedIndication3** | **Todo1** | **Todo2** | **Todo3** | **Todo4** | **Todo5** | **Note-display** | **Note** |
|  |  |  |  |  | **Y/N** | **Dose** | **Adm date** |  |  |  |  |  |  |  |  |  |  |
| **MenB-4C (Bexsero), MenB-FHbp (Trumenba)** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | Minimal age: 10 yrs ; MenB-4C and MenB-FHbp are not interchangeable; based on shared decision making |
| **Regular and catch-up schedule** | | | | | | | | | | | | | | | | | |
| Bexsero | 1 | >=16 yrs | <=18 yrs |  | N |  |  |  |  |  | Admin 1st dose | Schedule 2nd dose >= 4 wks from now |  |  |  |  |  |
| Trumenba | 2 | >= 16 yrs | <= 18 yrs |  | N |  |  |  |  |  | Admin 1st dose | Schedule 2nd dose >= 6 mon from now |  |  |  |  |  |
| Trumenba | 3 | >= 10 yrs | <= 25 yrs |  | Y | 2 | Interval < 6 mon between two doses |  |  |  | Schedule 3rd dose >= 4 mon from 2nd dose |  |  |  |  |  |  |
| Unknown | 4 | >= 10 yrs | <= 25 yrs |  | Y |  |  |  |  |  | Series restart with the same product, 2 doses |  |  |  |  |  |  |
| Benxsero and Trumenba | 5 | >= 10 yrs | <= 25 yrs |  | Y | 2 |  |  |  |  | One product needs to be selected and admin 2nd dose with correct interval to complete series |  |  |  |  |  |  |
| Trumenba | 6 | >= 10 yrs | <= 25 yrs |  | Y | 2 | Interval >= 6 mon |  |  |  | Do not admin 3rd dose |  |  |  |  |  |  |
| Trumenba | 7 | >= 10 yrs | <= 25 yrs |  | Y | 3 | Interval < 4 mon between 2nd and 3rd dose |  |  |  | Admin 4th dose >= 4 mon from 3rd dose |  |  |  |  |  |  |
| **Special situations** | | | | | | | | | | | | | | | | | |
| Persons with anatomic or functional asplenia (including sickle cell disease), persistent complement component deficiency, complement inhibitor (e.g., eculizumab, ravulizumab) use, microbiologists routinely exposed to isolates of Neisseria meningitidis, **persons who are at risk during an outbreak attributable to a vaccine serogroup** | | | | | | | | | | | | | | | | | |
| Bexsero | 8 | >= 10 yrs | <= 25 yrs |  | N |  |  |  |  |  | Admin 1st dose | Schedule 2nd dose >= 4 wks |  |  |  |  |  |
| Trumenba | 9 | >= 10 yrs | <= 25 yrs |  | N |  |  |  |  |  | Admin 1st dose | Schedule 2nd dose between (>= 4 wks AND <= 8 wks) from now | Scheudle 3rd dose = 6 mon from now |  |  |  |  |
| Bexsero or Trumenba for persons with HIV infection, who travel to or live in countries where meningococcal disease is hyperendemic or epidemic, college freshmen living in residence halls, or military recruits | | | | | | | | | | | | | | | | | |
|  | 10 |  |  |  |  |  |  |  |  |  | No recommendation |  |  |  |  |  |  |
| **Booster for persons with anatomic and functional asplenia (including sickle cell disease), persistent complement deficiencies (including patients using a complement inhibitor), for microbiologists routinely exposed to isolates of Neisseria meningitidis,** | | | | | | | | | | | | | | | | | |
| Bexsero or Trumenba | 11 | >= 10 yrs | <= 25 yts | Person remains at increased risks | Y |  | Complete primary vaccination |  |  |  | Single dose at 1 yr after completion of primary vaccination | Booster dose every 2-3 yrs thereafater |  |  |  |  |  |
| **Booster for persons who are at risk during an outbreak attributable to a vaccine serogroup** | | | | | | | | | | | | | | | | | |
| Bexsero or Trumenba | 12 | >= 10 yrs | <= 25 yrs | Person at increased risk during an outbreak | Y |  | Complete primary vaccination |  |  |  | Single dose if >= 1 yr after MenB primary vaccination completion |  |  |  |  |  |  |
| **With other vaccines** | | | | | | | | | | | | | | | | | |
|  | 13 |  |  |  |  |  |  |  |  |  | MenB vaccines can be administered simultaneously with other vaccines indicated for this age group, but at a different anatomic site |  |  |  |  |  |  |
| **Contraindications and precautions** | | | | | | | | | | | | | | | | | |
| Bexsero or Trumenba | 14 |  |  |  |  |  |  | Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component |  |  | Do not admin |  |  |  |  |  | Contraindication |
| Bexsero or Trumenba | 15 |  |  |  |  |  |  | Pregnancy |  |  | Admin only if benefits outweigh risks for an adverse reaction |  |  |  |  |  | Precaution |
| Bexsero or Trumenba | 16 |  |  |  |  |  |  | Moderate or severe acute illness with or without fever |  |  | Admin only if benefits outweigh risks for an adverse reaction |  |  |  |  |  | Precaution |
| Bexsero | 17 |  |  |  |  |  |  | Latex sensitivity |  |  | Admin only if benefits outweigh risks for an adverse reaction |  |  |  |  |  | Precaution |